EN DE
Watch Genome & Company for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Genome & Company (314130) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Genome & Company stock KRW 2,755, price KRW 3,300, that is 16.5% below the price, quality 46 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

GC Genome & Company logo Thin data Nov 10, 2026

Genome & Company

314130 · KQ
Expensive, weak quality

Our calculation puts a fair price 17% below what the stock costs today.

Low debt
Ranks above peers (6/10)
Quality 46/100
Expensive Growth (revenue 3y +20.4 %/yr in KRW)
Fair value 2,755 KRW · Overvalued
Loss-making · -169.1% net margin (TTM)
Negative free cash flow
Narrow moat 12/100
Thin data
Estimate
Watch Genome & Company for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

28,150 KRW 2,205 KRW Fair Value 2,755 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 2,205 KRW – 28,150 KRW · fair‑value band 2,066 KRW – 3,444 KRW · the 3,300 KRW price screens above the 2,755 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Genome & in your weekly email

Every Wednesday you see whether Genome & is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally.

Show moreShow less

Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities.

The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, cosmeceuticals, and dietary supplements.

In addition, it has a partnership with US Scioto Biosciences for the development of SB-121, which targets disorders related to the gut-brain axis, such as Autism Spectrum Disorder (ASD), as well as disorders related to gut-injury, including Necrotizing Enterocolitis (NEC). The company was founded in 2015 and is headquartered in Suwon-si, South Korea.

Stock analysis

Genome & Company (314130) currently trades at 3,300 KRW, while our estimate is 2,755 KRW, 17% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 2,066 KRW (bear) to 3,444 KRW (bull), the price of 3,300 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Genome & Company reported revenue of 24.6B KRW in FY2025 versus 451M KRW in FY2021, a compound +171.7%/yr. Reported net income was −6.4B KRW in FY2025.

Key figures

Market cap 159B KRW (≈ $119M) Micro · P/S ratio 6.50 · EPS (TTM) −915.51 KRW · Net margin −26.1% · Return on equity −47.1% · Return on assets (EBIT) −27.4% (5-year average) · Operating margin −128% · Revenue (TTM) 24.5B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 67% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −17%, 314130 screens richer than that median.

Fair Value

Bear 2,066 KRW Fair Value 2,755 KRW Bull 3,444 KRW
Price 3,300 KRW · Downside -16.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 4
How much profit the company makes from its sales and capital
Quality Growth 54
Are margins and returns getting better?
Cashflow 33
Do the profits arrive as real cash?
Financial strength 56
Debt, balance sheet and risk of trouble
Investment 95
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 44
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 31
Distance to the 52-week high, does not count
New shares 64
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−11.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−7,997.2% (2021) → −118.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

314130 screens overvalued: fair value 17% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Genome & Company with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 46 · Above median
Fair Value upside −16.5% · Above median
Profitability
Return on assets −4.4% · Above median
Net margin (12 months) −169.1% · Bottom 25%
Operating margin (12 months) −127.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 7.7% · Above median
Balance sheet
Debt / equity 0.09× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.50× · Cheaper than median
P/S (12 months) 6.50× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)11 · sector 0
FUTURE (revenue growth)39 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)96 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 314130
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 314130
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 314130
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 314130
argenx SE ARGX $971.55 $908.40 −7% vs 314130
CSL Limited CSL A$201.68 A$181.40 −10% vs 314130
Moderna, Inc MRNA $250.83 $158.70 −37% vs 314130
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 314130
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 314130
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 314130

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Genome & Company: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Genome & Company Fair Value". https://www.fairvalue-calculator.com/stock/314130

Frequently asked questions

Is Genome & Company (314130) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 2,755 KRW versus a price of 3,300 KRW, about 17% lower (overvalued).
What is the fair value of 314130?
Our estimate for Genome & Company is 2,755 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 3,300 KRW.
What is the quality score of 314130?
Genome & Company has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Genome & Company (314130)?
Our calculated price target is the estimate of 2,755 KRW (as of Nov 10, 2026). Cautious scenario 2,066 KRW, optimistic scenario 3,444 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Genome & Company stock forecast for 2026?
Our estimate puts fair value at 2,755 KRW, about 17% lower versus a price of 3,300 KRW (overvalued). Cautious scenario 2,066 KRW, optimistic scenario 3,444 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Genome & Company (314130)?
Genome & Company reported trailing-twelve-month revenue of about 24.5B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Genome & Company (314130)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Genome & Company it is 2,755 KRW per share (as of Nov 10, 2026), against a price of 3,300 KRW.
Is Genome & Company stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 314130 trades above its calculated fair value: price 3,300 KRW, fair value 2,755 KRW, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 314130?
No. The price is what the market pays today (3,300 KRW); the fair value is what the company's own numbers justify (2,755 KRW). For Genome & Company the two are 544.92 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Genome & Company worth?
The market values Genome & Company at about 159B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 3,300 KRW; our models calculate a fair value of 2,755 KRW per share.
What do the bullish and bearish scenarios say about 314130?
Our models span a range for Genome & Company: cautious scenario 2,066 KRW, base 2,755 KRW, optimistic 3,444 KRW per share (as of Nov 10, 2026, price 3,300 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Genome & Company (314130)?
Balance-sheet figures for Genome & Company (as of Nov 10, 2026): return on equity −47.1%, debt of 0.09 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 314130 from its 52-week high?
Genome & Company trades at 3,300 KRW, about 67% below its 52-week high of 9,970 KRW and 20% above the low of 2,750 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 2,755 KRW is for.
Which stocks are comparable to Genome & Company?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Genome & Company stock attractive at the current price?
The data as of Nov 10, 2026: price 3,300 KRW, calculated fair value 2,755 KRW (−17%), Quality Score 46/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Genome & Company itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Genome & Company (314130)?
The closing price on Nov 10, 2026 was 3,300 KRW. Our estimate is 2,755 KRW, about 17% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Genome & Company right now?
Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Genome & Company

How large is the market capitalisation of Genome & Company (314130)?
The market capitalisation of Genome & Company is 159B KRW (≈ $119M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Genome & Company (314130)?
The price-to-sales ratio of Genome & Company is 6.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Genome & Company (314130)?
Earnings per share at Genome & Company are −915.51 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Genome & Company (314130)?
The net margin of Genome & Company is −26.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Genome & Company (314130)?
The return on equity (ROE) of Genome & Company is −47.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Genome & Company (314130)?
On an EBIT basis the return on assets of Genome & Company is −27.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Genome & Company (314130)?
The operating margin of Genome & Company is −128% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Genome & Company (314130)?
Revenue at Genome & Company is growing +7.7% versus a year earlier (3y avg +20.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Genome & Company (314130) generate?
The free cash flow of Genome & Company is −18.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Genome & Company in the live analysis

One click puts Genome & Company on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.